Charikleia Kelaidi

Dr. Charikleia Kelaidi

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2021 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
MFMaarten Fornerod
Maarten Fornerod
JMJing Ma
Jing Ma
SNSanne Noort
Sanne Noort
YLYu Liu
Yu Liu
MWMichael P. Walsh
Michael P. Walsh
TGTanja A. Gruber
Tanja A. Gruber
Genomic characterization of pediatric patients with acute myeloid leukemia (AML) has led to the discovery of somatic mutations with prognostic implications. Although gene-expression profiling can differentiate subsets of pediatric AML, its clinical utility in risk stratification remains limited. Here, we evaluate gene expression, pathogenic somatic mutations, and outcome in a cohort of 435 pediatric patients with a spectrum of pediatric myeloid-related acute leukemias for biological subtype discovery. This analysis revealed 63 patients with varying immunophenotypes that span a T-lineage and myeloid continuum designated as acute myeloid/T-lymphoblastic leukemia (AMTL). Within AMTL, two patient subgroups distinguished by FLT3-ITD and PRC2 mutations have different outcomes, demonstrating the impact of mutational composition on survival. Across the cohort, variability in outcomes of patients within isomutational subsets is influenced by transcriptional identity and the presence of a stem cell–like gene-expression signature. Integration of gene expression and somatic mutations leads to improved risk stratification. Significance: Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found that a combination of genetic and transcriptional readouts was superior to immunophenotype and genomic mutations in identifying biological subtypes and predicting outcomes. This article is highlighted in the In This Issue feature, p. 549

30 November 2011 in Leukemia Research
Verified
Journal Article
Closed access
PDF file
Sophie ParkSophie Park
Sophie Park
RSR. Sapena
R. Sapena
CKCharikleia Kelaidi
Charikleia Kelaidi
DVD. Vassilieff
D. Vassilieff
DBD. Bordessoule
D. Bordessoule
FDF. Dreyfus
F. Dreyfus

3 January 2011 in Mediterranean Journal of Hematology and Infectious Diseases
Verified
Journal Article
Open access
PDF file
CKCharikleia Kelaidi
Charikleia Kelaidi
LALionel Ades
Lionel Ades
PFPierre Fenaux
Pierre Fenaux
Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.

26 May 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
KAKondylia Antoniadi
Kondylia Antoniadi
Nikolaos ThomaidisNikolaos Thomaidis
Nikolaos Thomaidis
PNPetros Nihoyannopoulos
Petros Nihoyannopoulos
KTKonstantinos Tsioufis
Konstantinos Tsioufis
Evangelos GikasEvangelos Gikas
Evangelos Gikas
SPSophia Polychronopoulou
Sophia Polychronopoulou
Improvements in the treatment of childhood cancer have considerably enhanced survival rates over the last decades to over 80% as of today. However, this great achievement has been accompanied by the occurrence of several early and long-term treatment-related complications major of which is cardiotoxicity. This article reviews the contemporary definition of cardiotoxicity, older and newer chemotherapeutic agents that are mainly involved in cardiotoxicity, routine process diagnoses, and methods using omics technology for early and preventive diagnosis. Chemotherapeutic agents and radiation therapies have been implicated as a cause of cardiotoxicity. In response, the area of cardio-oncology has developed into a crucial element of oncologic patient care, committed to the early diagnosis and treatment of adverse cardiac events. However, routine diagnosis and the monitoring of cardiotoxicity rely on electrocardiography and echocardiography. For the early detection of cardiotoxicity, in recent years, major studies have been conducted using biomarkers such as troponin, N-terminal pro b-natriuretic peptide, etc. Despite the refinements in diagnostics, severe limitations still exist due to the increase in the above-mentioned biomarkers only after significant cardiac damage has occurred. Lately, the research has expanded by introducing new technologies and finding new markers using the omics approach. These new markers could be used not only for early detection but also for the early prevention of cardiotoxicity. Omics science, which includes genomics, transcriptomics, proteomics, and metabolomics, offers new opportunities for biomarker discovery in cardiotoxicity and may provide an understanding of the mechanisms of cardiotoxicity beyond traditional technologies.

15 June 2021 in Familial Cancer
Verified
Journal Article
Closed access
PDF file
CKCharikleia Kelaidi
Charikleia Kelaidi
VTV. Tzotzola
V. Tzotzola
SPS. Polychronopoulou
S. Polychronopoulou

31 December 2020 in Acta Paediatrica
Verified
Journal Article
Closed access
PDF file
VTVasiliki Tzotzola
Vasiliki Tzotzola
LPLoizos Petrikkos
Loizos Petrikkos
VPVassilios Papadakis
Vassilios Papadakis
GMGeorgia Mitropoulou
Georgia Mitropoulou
CKCharikleia Kelaidi
Charikleia Kelaidi
SPSophia Polychronopoulou
Sophia Polychronopoulou